imara
announces
first
patient
dosed
forte
phase
clinical
trial
nasdaq
imra
boston
globe
newswire
imara
nasdaq
imra
biopharmaceutical
company
dedicated
developing
commercializing
novel
therapeutics
treat
patients
suffering
rare
inherited
genetic
disorders
hemoglobin
today
announced
dosing
first
patient
company
forte
phase
clinical
trial
patients
currently
approved
oral
therapies
increase
fetal
hemoglobin
rare
inherited
red
blood
cell
disorder
left
untreated
causes
severe
anemia
enlarged
spleen
skeletal
abnormalities
organ
failure
early
death
said
perla
eleftheriou
consultant
hematologist
red
cell
hematology
department
university
college
london
hospitals
nhs
foundation
trust
honorary
clinical
senior
lecturer
university
college
london
national
lead
investigator
united
kingdom
forte
trial
believe
clear
rationale
expand
development
include
look
forward
working
alongside
multiple
clinical
centers
globally
advance
forte
clinical
dosing
first
patient
forte
phase
clinical
trial
marks
important
milestone
imara
begin
clinical
evaluation
first
time
patients
said
rahul
ballal
president
chief
executive
officer
imara
multiple
preclinical
studies
show
treatment
enhances
maturation
production
red
blood
cells
looking
forward
advancing
potentially
transformative
oral
therapy
ballal
continued
patient
dosing
forte
clinical
trial
follows
initiation
dosing
august
ardent
phase
clinical
trial
patients
sickle
cell
disease
advancements
transform
imara
company
drug
candidate
multiple
indications
across
global
clinical
trials
managing
various
clinical
manifestations
sickle
cell
disease
complex
patients
around
world
accessible
treatment
options
imara
remain
committed
working
together
clinical
trial
partners
investigators
patient
community
evaluate
therapeutic
potential
oral
potentially
treatment
rare
inherited
blood
global
randomized
multicenter
forte
phase
clinical
trial
evaluate
safety
tolerability
approximately
adult
patients
patient
randomization
stratified
transfusion
dependence
tdt
dependence
ntdt
dosing
employed
optimize
drug
exposure
tolerability
tdt
patients
clinical
trial
also
evaluate
effect
versus
placebo
reducing
average
number
days
red
blood
cell
transfusions
change
iron
load
rate
result
transfusion
ntdt
patients
effect
versus
placebo
fetal
hemoglobin
well
anemia
also
evaluated
forte
trial
also
examine
pharmacokinetic
additional
exploratory
efficacy
endpoints
interim
analyses
planned
trial
first
interim
analysis
conducted
patients
reached
weeks
treatment
additional
interim
analysis
conducted
patients
reached
weeks
treatment
information
forte
trial
visit
https
show
highly
selective
potent
small
molecule
inhibitor
selectively
degrades
cyclic
guanosine
monophosphate
cgmp
active
signaling
molecule
plays
role
vascular
biology
lower
levels
cgmp
found
people
scd
associated
reduced
blood
flow
increased
inflammation
greater
cell
adhesion
reduced
nitric
oxide
mediated
vasodilation
blocking
acts
increase
cgmp
levels
associated
reactivation
fetal
hemoglobin
hbf
natural
hemoglobin
produced
fetal
development
increased
levels
hbf
rbcs
demonstrated
improve
symptomology
substantially
lower
disease
burden
patients
scd
patients
hemoglobinopathy
rare
inherited
red
blood
cell
disorder
presents
spectrum
disease
patients
categorized
based
hemoglobin
levels
genotype
clinical
manifestations
left
untreated
disease
causes
severe
anemia
splenomegaly
skeletal
abnormalities
organ
failure
early
death
prevalence
globally
estimated
incidence
births
per
year
especially
prevalent
developing
countries
africa
south
asia
southeast
asia
mediterranean
region
middle
east
total
combined
prevalence
beta
thalassemia
european
union
united
states
estimated
approximately
patients
imara
imara
biotechnology
company
dedicated
developing
commercializing
novel
therapeutics
treat
patients
suffering
rare
inherited
genetic
disorders
hemoglobin
imara
currently
advancing
highly
selective
potent
small
molecule
inhibitor
oral
potentially
treatment
sickle
cell
disease
designed
multimodal
mechanism
action
acts
red
blood
cells
white
blood
cells
adhesion
mediators
cell
types
information
please
visit
cautionary
note
regarding
statements
statements
press
release
future
expectations
plans
prospects
well
statements
regarding
matters
historical
facts
may
constitute
statements
within
meaning
private
securities
litigation
reform
act
statements
include
limited
statements
eleftheriou
ballal
statements
relating
design
forte
phase
clinical
trial
company
beliefs
regarding
therapeutic
potential
advancement
clinical
program
words
anticipate
believe
continue
could
estimate
expect
intend
may
plan
potential
predict
project
target
would
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
actual
results
may
differ
materially
indicated
statements
result
various
important
factors
including
impact
extraordinary
external
events
risks
uncertainties
resulting
impact
pandemic
company
business
operations
strategy
goals
anticipated
milestones
company
ability
advance
development
timelines
projects
current
future
clinical
trials
demonstrate
current
future
clinical
trials
requisite
safety
efficacy
replicate
scientific
data
clinical
trials
obtain
maintain
necessary
regulatory
approvals
obtain
maintain
enforce
necessary
patent
intellectual
property
protection
identify
enter
maintain
collaboration
agreements
third
parties
manage
competition
manage
expenses
raise
substantial
additional
capital
needed
achieve
business
objectives
attract
retain
qualified
personnel
successfully
execute
business
strategies
factors
discussed
risk
factors
section
company
recent
quarterly
report
form
file
securities
exchange
commission
filings
company
makes
securities
exchange
commission
future
statements
contained
press
release
speak
date
hereof
company
expressly
disclaims
obligation
update
statement
whether
result
new
information
future
events
otherwise
media
contact
gina
nugent
ten
bridge
communications
gina
investor
contact
michael
gray
mgray
